The drug ACLACINON contains one active pharmaceutical ingredient (API):
Aclarubicin is an anthracycline antibiotic produced by Streptomyces galilaeus and also has potent antineoplastic activity. It is less cardiotoxic than doxorubicin and daunorubicin. The mechanism of action of aclarubicin is based on its capacity to insert its trisaccharide chain into the minor DNA groove: poison of topoisomerase I, inhibitor of topoisomerase II, eviction of histones from nucleosomes, but also inhibitor of the 20S proteasome.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Japan
This drug has been assigned below unique identifiers within the countries it is being marketed: